Piper Sandler analyst Do Kim raised the firm’s price target on Gilead to $111 from $104 and keeps an Overweight rating on the shares. The analyst sees potential upside to guidance for both Trodelvy and Veklury. Kim believes strong Q4 HIV sales will support a return to pre-pandemic growth, while also providing confidence that HIV will grow low-to-mid single digits in FY23.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on GILD:
- Truist biotech analyst to hold an industry dinner meeting
- Hookipa Pharma achieves $5M milestone payment from Gilead
- EVOQ to potentially receive $658.5M in Gilead collaboration on immunotherapies
- RBC downgrades Gilead, says drivers need time to play out
- Gilead downgraded to Sector Perform from Outperform at RBC Capital
